Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854373 · ClinicalTrials.gov registry record · Phase 4
Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
A Phase 4 study of Infertility, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 232
- Enrollment target
- 1
- Study location
NCT00854373 is a Phase 4 study of Infertility that has completed, run by University of California, San Francisco. The registered enrollment target is 232 participants, below the 7,586-participant average among 74 other Infertility trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00854373, a Phase 4 study of Infertility, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 232 participants
- Enrollment target
- 1
- Study location
Study Summary
Marcelle Cedars, M.D., Victor Fujimoto, M.D., Mitch Rosen, M.D., Heather Huddleston, M.D., Paolo Rinaudo, M.D., Anthony Dobson, M.D., and Shehua Shen, M.D. from the UCSF Department of Obstetrics and Gynecology and Reproductive Sciences are conducting a study to learn about ovarian stimulation and oocyte maturation to improve fertilization, embryo quality, implantation and clinical pregnancy rates in patients undergoing in vitro fertilization (IVF). Two hormones, follicle stimulating hormone and human chorionic gonadotropin (FSH/hCG) will be compared to the standard one hormone, hCG, for the ovulation trigger. Over the past two decades, the success rate of assisted reproductive technology (ART) has dramatically increased. This increase has largely been attributed to improvements in the laboratory conditions and improvements in ovarian stimulation protocols (those medications used to increase the number of eggs maturing each cycle). Less work has been done on different ways to cause the final maturation of the eggs and the release of the egg from the ovary. The investigators propose to change the final injection prior to the egg retrieval (the ovulation trigger) so that it looks more like what happens in a normal menstrual cycle, where two hormones (both luteinizing hormone (LH) and FSH) increase. The investigators want to find out if this will improve egg quality and increase chances for pregnancy.
Conditions Studied
Interventions
- DRUG Bravelle(follicle stimulating hormone)
- OTHER Saline ( placebo)
Study Locations (1)
California
- UCSF- Mission Bay - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2007-06-01 |
| Est. Completion | 2010-04-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00854373
The ClinicalTrials.gov registry entry for NCT00854373 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,586-participant average among 74 other Infertility trials with a reported enrollment target (97% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infertility appearing as the primary indexed condition, and to 2 interventions - of which Bravelle(follicle stimulating hormone) is the first listed.
NCT00854373 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00854373 about?
NCT00854373 is a clinical study titled "Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial". Marcelle Cedars, M.D., Victor Fujimoto, M.D., Mitch Rosen, M.D., Heather Huddleston, M.D., Paolo Rinaudo, M.D., Anthony Dobson, M.D., and Shehua Shen, M.D. from the UCSF Department of Obstetrics and Gynecology and Reproductive Sciences are conducting a study to learn about ovarian stimulation and oo...
What is the current status of trial NCT00854373?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 232 participants. The study started on 2007-06-01. Estimated completion is 2010-04-20.
What conditions does trial NCT00854373 study?
This clinical trial studies the following conditions: Infertility.
What interventions are being tested in trial NCT00854373?
The interventions under investigation include: Bravelle(follicle stimulating hormone) (DRUG), Saline ( placebo) (OTHER).
Who is sponsoring clinical trial NCT00854373?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00854373 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GnRH for Luteal Support in IVF/ICSI/FET Cycles
RECRUITING · Phase 4
-
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
ACTIVE NOT RECRUITING · Phase 4
-
Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
COMPLETED · Phase 4
-
Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer
COMPLETED · Phase 4
-
Menopur Mixed Protocol
COMPLETED · Phase 4
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.